Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Catalent, Inc
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
- Contract Research, Toxicology Testing-CRO
- OTC, Consumer
- Controlled Release
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Accucaps Industries Limited
- Catalent U.K. Swindon Zydis Limited
- Cook Pharmica LLC
- Juniper Pharmaceuticals
- Molecular Profiles Ltd.
- Columbia Laboratories, Inc.